Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Short term Debt (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Short term Debt over the past 14 years, most recently at $773000.0 for Q4 2024.

  • Quarterly results put Short term Debt at $773000.0 for Q4 2024, changed 0.0% from a year ago — trailing twelve months through Nov 2024 was $773000.0 (changed 0.0% YoY), and the annual figure for FY2024 was $773000.0, up 33.28%.
  • Short term Debt for Q4 2024 was $773000.0 at Lifecore Biomedical, Inc. \De\, roughly flat from $773000.0 in the prior quarter.
  • Over the last five years, Short term Debt for LFCR hit a ceiling of $98.2 million in Q2 2022 and a floor of $580000.0 in Q2 2023.
  • Median Short term Debt over the past 5 years was $32.0 million (2021), compared with a mean of $32.3 million.
  • Biggest five-year swings in Short term Debt: surged 604.73% in 2020 and later crashed 99.41% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Short term Debt stood at $77.0 million in 2020, then tumbled by 45.45% to $42.0 million in 2021, then grew by 14.29% to $48.0 million in 2022, then tumbled by 98.39% to $773000.0 in 2023, then changed by 0.0% to $773000.0 in 2024.
  • The last three reported values for Short term Debt were $773000.0 (Q4 2024), $773000.0 (Q3 2024), and $773000.0 (Q2 2024) per Business Quant data.